Get the Stockscreener App
66.53
0.15%
0.10
After Hours:
66.53
Biomarin Pharmaceutical Inc stock is traded at $66.53, with a volume of 2.30M.
It is up +0.15% in the last 24 hours and up +9.57% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$66.43
Open:
$65.785
24h Volume:
2.30M
Relative Volume:
1.08
Market Cap:
$12.88B
Revenue:
$3.29B
Net Income/Loss:
$268.74M
P/E Ratio:
48.55
EPS:
1.3704
Net Cash Flow:
$759.12M
1W Performance:
+2.88%
1M Performance:
+9.57%
6M Performance:
+10.09%
1Y Performance:
+17.23%
1-Day Range:
$65.52
$66.64
1-Week Range:
$64.33
$67.69
52-Week Range:
$49.26
$70.98
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
66.53 | 13.10B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Resumed | Morgan Stanley | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-20-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks - RTTNews
NFJ Investment Group LLC Takes Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
40,919 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Paralel Advisors LLC - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Raised to "Strong-Buy" at BMO Capital Markets - MarketBeat
Eagle Health Investments LP Acquires Shares of 624,676 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Edmond DE Rothschild Holding S.A. Purchases Shares of 687,030 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Boehringer again rises up rare disease reputation rankings - Fierce Pharma
Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today - Yahoo Finance
BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases - Yahoo Finance
BMRN Looks 16.4% Undervalued on GF Value™ Amid Market Concerns Over Voxzogo - GuruFocus
BioMarin initiated an outperform at BMO as Voxzogo erosion overstated - Seeking Alpha
BioMarin Pharmaceutical Market Sentiment - Benzinga France
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment - Zacks Investment Research
BIOMARIN PHARMACEUTICAL INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $98 - Bitget
Canaccord reiterates BioMarin stock rating on Alesta acquisition By Investing.com - Investing.com South Africa
H.C. Wainwright cuts BioMarin stock price target on acquisition costs By Investing.com - Investing.com South Africa
BMO Capital Markets Initiates Coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga
BMO initiates BioMarin stock with Outperform, $98 price target By Investing.com - Investing.com South Africa
Canaccord reiterates BioMarin stock rating on Alesta acquisition - Investing.com
H.C. Wainwright cuts BioMarin stock price target on acquisition costs - Investing.com
BMRN Initiated Coverage by BMO Capital -- Rating Set at Outperform - GuruFocus
BioMarin to Acquire RTW Biotech Portfolio Company Alesta Therapeutics for Up to $490 Million - Kalkine Media
BMO initiates BioMarin stock with Outperform, $98 price target - Investing.com
BioMarin to acquire Alesta Therapeutics for up to $490 million By Investing.com - Investing.com Australia
GSA Capital Partners LLP Invests $944,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
BioMarin to acquire Alesta Therapeutics for up to $490 million - Investing.com
REGRTW Biotech Opp.BioMarin to acquire Alesta Therapeutics - TradingView
BioMarin to acquire Alesta Therapeutics for $275M upfront By Investing.com - Investing.com Nigeria
BioMarin to Acquire Alesta in Cash Deal, Betting on First Oral HPP Therapy - nai500.com
BioMarin Buying Alesta Therapeutics For Up To $490M - Law360
BMRN Looks 19.4% Undervalued on GF Value™ - GuruFocus
BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company - The Business Journals
BioMarin snaps up Alesta's lead asset for $275m - pharmaphorum
BioMarin Pays $275M Upfront for Alesta to Challenge AstraZeneca in Rare Bone Disease - finance.biggo.com
BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment - Benzinga
BioMarin to Acquire Alesta Therapeutics for Up to $490 Million - citybiz
BioMarin acquires experimental drug for rare bone disorder in $275M deal - BioPharma Dive
BMRN Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
BioMarin stock surges on $275M Alesta acquisition deal By Investing.com - Investing.com Australia
HC Wainwright Has Lowered Expectations for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351 - Pharmaceutical Executive
BioMarin stock surges on $275M Alesta acquisition deal - Investing.com
BioMarin Shares Jump After $275 Million Deal to Acquire Alesta Therapeutics - Yahoo Finance
Form 8K Biomarin Pharmaceutical Inc For: 18 August By Investing.com - Investing.com Nigeria
BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca - Fierce Biotech
BioMarin Pharmaceutical to Acquire Alesta Therapeutics for up to $490 Million - marketscreener.com
BioMarin to acquire Alesta Therapeutics for $275M upfront - Investing.com
BioMarin to acquire Alesta for $275M upfront (BMRN:NASDAQ) - Seeking Alpha
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline - PR Newswire
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):